Of the 37 candidate genes and five strongest predicted genes, drugs for GATA3, IL33, IL1RL1, SMAD3, and TSLP are either already in use or in clinical trials for asthma, clearly validating these genes from our pipeline as therapeutic targets. This evidence concerns the gene SMAD3 and asthma.